Show simple item record

dc.contributor.authorThurber, Greg M.
dc.contributor.authorSchmidt, Michael M.
dc.contributor.authorRhoden, John J.
dc.contributor.authorWittrup, Karl Dane
dc.date.accessioned2016-02-29T17:12:17Z
dc.date.available2016-02-29T17:12:17Z
dc.date.issued2012
dc.identifier.isbn9780123969620
dc.identifier.issn00766879
dc.identifier.urihttp://hdl.handle.net/1721.1/101376
dc.description.abstractTheoretical analyses of targeting agent pharmacokinetics provides specific guidance with respect to desirable design objectives such as agent size, affinity, and target antigen. These analyses suggest that IgG-sized macromolecular constructs exhibit the most favorable balance between systemic clearance and vascular extravasation, resulting in maximal tumor uptake. Quantitative predictions of the effects of dose and binding affinity on tumor uptake and penetration are also provided. The single bolus dose required for saturation of xenografted tumors in mice can be predicted from knowledge of antigen expression level and metabolic half-life. The role of high binding affinity in tumor uptake can be summarized as: essential for small peptides, less important for antibodies, and negligible for nanoparticles.en_US
dc.language.isoen_US
dc.publisherElsevieren_US
dc.relation.isversionofhttp://dx.doi.org/10.1016/b978-0-12-396962-0.00010-0en_US
dc.rightsCreative Commons Attribution-NonCommercial-NoDerivs Licenseen_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/en_US
dc.sourcePMCen_US
dc.titlePractical Theoretic Guidance for the Design of Tumor-Targeting Agentsen_US
dc.typeArticleen_US
dc.identifier.citationWittrup, K. Dane, Greg M. Thurber, Michael M. Schmidt, and John J. Rhoden. “Practical Theoretic Guidance for the Design of Tumor-Targeting Agents.” Protein Engineering for Therapeutics, Part B (2012): 255–268.en_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Biological Engineeringen_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Chemical Engineeringen_US
dc.contributor.departmentKoch Institute for Integrative Cancer Research at MITen_US
dc.contributor.mitauthorWittrup, Karl Daneen_US
dc.contributor.mitauthorThurber, Greg M.en_US
dc.contributor.mitauthorSchmidt, Michael M.en_US
dc.contributor.mitauthorRhoden, John J.en_US
dc.relation.journalProtein Engineering for Therapeutics, Part Ben_US
dc.eprint.versionAuthor's final manuscripten_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dspace.orderedauthorsWittrup, K. Dane; Thurber, Greg M.; Schmidt, Michael M.; Rhoden, John J.en_US
dc.identifier.orcidhttps://orcid.org/0000-0003-2398-5896
dc.identifier.orcidhttps://orcid.org/0000-0001-7570-2080
mit.licensePUBLISHER_CCen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record